01OverviewDefinition, clinical context and the essential points that orientate the chapter.
Ductal carcinoma in situ is a clonal malignant proliferation within the duct-lobular system that remains bounded by myoepithelial cells and basement membrane. It is commonly detected through calcification rather than symptoms. Low, intermediate and high nuclear grade describe biological features and necrosis may produce branching or pleomorphic calcification. The diagnosis matters because some lesions progress to invasive cancer, yet not every untreated focus would do so within a patient’s lifetime.
Treatment balances prevention of ipsilateral invasive and in-situ recurrence against the consequences of surgery and radiotherapy. Distribution, breast size, grade, necrosis, symptoms, patient health and preferences shape the operation. A core labelled DCIS is a preoperative sample, not proof that the whole lesion lacks invasion. This sampling limit explains why high-risk conservation cases may need sentinel staging and why mastectomy cases receive sentinel-node biopsy during the same anaesthetic.
Key points
- DCIS consists of malignant epithelial cells confined within breast ducts by an intact basement membrane; it has no direct metastatic capacity until invasion occurs.
- Most screen-detected DCIS presents as mammographic microcalcification. Core biopsy defines grade and pattern but can underestimate invasive cancer because it samples only part of the lesion.
- Definitive management removes the involved breast area with conservation plus consideration of radiotherapy, or mastectomy when disease extent prevents acceptable conservation.
- Do not routinely perform sentinel-node biopsy with breast-conserving surgery for preoperative DCIS unless invasion risk is high, such as a palpable mass or extensive microcalcification.
- Offer sentinel-node biopsy at mastectomy for DCIS because lymphatic mapping becomes unreliable after breast removal and occult invasion cannot be excluded completely beforehand.
- After breast conservation, offer further surgery for tumour on ink at a radial margin; for pure DCIS more than 0 mm but less than 2 mm from a radial margin, consider further surgery through individualised discussion.
02AetiologyUnderlying causes, associations and risk factors, with why each one matters.
Clonal epithelial neoplasia
Acquired molecular changes allow one ductal epithelial population to expand abnormally while remaining bounded within the duct-lobular system.
Predisposing breast risk
Older age, familial susceptibility and prior proliferative atypia increase background breast-cancer risk, but an individual DCIS lesion often has no single identifiable cause.
03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.
- 1Intraductal proliferation
Atypical malignant cells replace normal ductal epithelium but remain separated from breast stroma by myoepithelial cells and basement membrane.
- 2Central necrosis and calcification
Rapidly proliferating high-grade cells may undergo comedo necrosis; dystrophic mineral deposition makes the lesion visible as suspicious mammographic calcification.
- 3Ductal extension
Cells track along branching duct units, so the mammographic span can be larger and less spherical than a simple mass diameter suggests.
- 4Potential progression
Further change can permit basement-membrane breach and invasive carcinoma, but the probability and timing vary substantially between lesions.
04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.
Fine pleomorphic, linear or branching calcifications in a segmental distribution can represent necrotic or secretory material within involved ducts.
A minority present with a mass, nipple discharge or Paget change; a palpable component raises the chance that invasive disease is present.
The defining feature is malignant epithelial proliferation without stromal invasion. Grade, necrosis, architecture and receptor status contribute to planning.
Calcification can trace a branching duct system. Radiological span, multiple groups and breast-to-disease ratio influence whether conservation is practical.
05InvestigationsWhat to request, why it matters and how to interpret it.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Diagnostic magnification mammographyFirst step - Why
- Characterise calcification morphology and map its full distribution before biopsy and surgery.
- Interpretation and limitations
- Suspicious calcification requires representative image-guided tissue. Measurements should include the complete relevant field rather than only the densest cluster.
- 02
Stereotactic or tomosynthesis-guided core biopsy - Why
- Sample mammographic calcification that lacks a reliable ultrasound target.
- Interpretation and limitations
- Specimen radiography should confirm calcification within cores. DCIS on core may be upgraded to invasive cancer at definitive excision.
- 03
Histopathology review - Why
- Report DCIS grade, architecture, necrosis, size in excision and the relationship to radial margins.
- Interpretation and limitations
- Tumour on ink means a 0 mm radial margin. A close margin without cells on ink is interpreted differently for pure DCIS and invasive disease under current NICE thresholds.
- 04
Selected breast MRI - Why
- Resolve extent only when examination and conventional imaging are discordant or breast density prevents reliable sizing.
- Interpretation and limitations
- NICE does not recommend routine MRI for every DCIS. Additional MRI-only lesions need targeted confirmation if they would alter the operation.
06Differential diagnosisRealistic alternatives and the features that help distinguish them.
Atypical ductal hyperplasia
A smaller or incompletely developed atypical intraductal proliferation can resemble low-grade DCIS and requires careful quantitative pathological distinction.
Invasive carcinoma
Stromal invasion changes nodal and systemic implications; small invasive foci may be absent from core samples but found at excision.
Benign secretory calcification
Vascular, dermal, involutional and secretory calcifications can be benign; morphology and distribution guide whether tissue sampling is necessary.
Lobular carcinoma in situ
LCIS is a marker and non-obligate precursor with different distribution, pathology and management from duct-centred in-situ carcinoma.
07ManagementImmediate care, first-line treatment, alternatives and escalation.
01Screen-detected DCIS pathwayConfirm target, extent and operative routeFirst stepA 57-year-old has a 28 mm cluster of pleomorphic calcification; stereotactic cores contain high-grade DCIS without invasion.+
- 1Confirm specimen radiography demonstrated the target calcification and ask pathology and radiology whether the result explains the imaging appearance.
- 2Map the complete mammographic extent, examine the patient and identify factors increasing underestimation risk, including a mass or extensive calcification.
- 3Discuss breast-conserving excision if acceptable margins and cosmesis appear achievable; discuss mastectomy and reconstruction if distribution is too extensive for conservation.
- 4If conservation is selected without high-risk features, omit routine sentinel-node biopsy; if mastectomy is selected, offer sentinel-node biopsy during that operation.
- 5Review final histology for invasion, measured extent and radial margins, then agree radiotherapy and any further surgery at the postoperative multidisciplinary meeting.
02Close-margin pathwayApply the DCIS-specific thresholdPure DCIS is excised with no tumour on ink, but cells lie 1 mm from a radial margin.+
- 1Confirm that the measured margin is radial and that there is no invasive component or tumour actually touching ink.
- 2Consider re-excision or mastectomy rather than treating the 1 mm distance as an automatic command; discuss recurrence reduction, likely residual burden and radiotherapy.
- 3Include breast size, cosmetic cost, comorbidity and the patient’s priorities in the decision and record the agreed balance.
- 4If no further surgery is chosen, ensure the radiotherapy plan and follow-up reflect the complete pathological and imaging context.
03Unexpected invasion pathwayRestage after pathological upgradeFinal conservation histology reveals a 5 mm invasive focus within the DCIS specimen and no sentinel-node biopsy was performed.+
- 1Request complete invasive tumour profiling and review margin status separately for invasive and in-situ components.
- 2Reassess the axilla clinically and with ultrasound; sample any morphologically abnormal node.
- 3Discuss whether delayed sentinel-node staging is technically appropriate within the local validated service or whether nodal information would change treatment.
- 4Explain why the diagnosis changed: the original core sampled DCIS correctly but did not contain the small invasive focus present elsewhere.
08ComplicationsImportant consequences, why they occur and why they matter clinically.
Ipsilateral DCIS recurrence
Residual or new in-situ disease can recur in the treated breast, particularly when local control is incomplete or adverse features coexist.
Ipsilateral invasive recurrence
A later invasive cancer carries nodal and distant-spread potential, which is the major event that preventive DCIS treatment aims to reduce.
Occult invasion at excision
Definitive pathology may upgrade a core diagnosis when a separate invasive focus is found, prompting receptor and nodal reassessment.
Treatment consequences
Re-excision, mastectomy and radiotherapy can affect sensation, appearance, shoulder function and psychological wellbeing despite excellent cancer-specific outcomes.
09Monitoring and follow-upTreatment response, safety checks and longer-term review.
- Before surgery, reconcile the mammographic extent with biopsy site and clip position so the removed specimen corresponds to the diagnosed calcification.
- At postoperative review, document final DCIS size and grade, any invasion, radial margin distances and whether additional surgery or radiotherapy is advised.
- After treatment, NICE recommends annual mammography for five years, continuing thereafter until the person enters the relevant population screening programme where applicable.
- Investigate a new ipsilateral or contralateral lump, nipple change or suspicious calcification as a fresh diagnostic problem; scheduled surveillance does not replace symptom assessment.
10Special situationsVariants, exceptions and circumstances that change the usual approach.
In situ means anatomically confined
DCIS is cytologically malignant but remains within the ductal basement membrane, so nodes are not staged routinely unless occult invasion is plausible or mastectomy prevents later mapping.
Core can under-sample
An accurate DCIS core diagnosis may coexist with unsampled invasion elsewhere in an extensive or mass-forming lesion; this is sampling limitation, not necessarily pathology error.
Margin rules are diagnosis-specific
Current NICE advice distinguishes tumour on ink from close clear margins and uses different “consider” thresholds for pure DCIS and invasive cancer.
Radiotherapy changes local recurrence
After complete breast-conserving surgery, radiotherapy is considered to reduce ipsilateral recurrence; it does not correct an inadequately assessed or involved surgical margin.
Endocrine treatment after ER-positive DCIS
After breast-conserving surgery for ER-positive DCIS, NICE advises discussing endocrine treatment's benefits and harms. Offer it if radiotherapy was recommended but was not received; consider it if radiotherapy was not recommended. Explain the recurrence benefit and lack of demonstrated survival benefit at 5 or 10 years, considering baseline recurrence risk and adverse effects. This postoperative DCIS decision is distinct from primary prevention in an unaffected high-risk woman; drug selection and prescribing follow the individual postoperative breast oncology plan.
11Common pitfallsFrequent interpretation and management errors.
- 01
Describing DCIS as harmless because it is non-invasive ignores its potential progression and the possibility of occult invasion within the unsampled lesion.
- 02
Performing routine axillary clearance for pure DCIS exposes the patient to lymphoedema without a metastatic route from genuinely in-situ disease.
- 03
Omitting sentinel-node biopsy during mastectomy for DCIS can remove the opportunity for reliable later staging if definitive histology shows invasion.
- 04
Treating every 1 mm pure-DCIS margin as mandatory mastectomy misstates NICE, which asks clinicians to consider further surgery through individualised decision-making.